Cytokinetics Has Doubled Since May. Does It Still Have Steam?

Cytokinetics secured its first FDA approval for aficamten, rebranded Myqorzo, for obstructive hypertrophic cardiomyopathy, prompting an after-hours share jump. Leerink analyst Roanna Ruiz highlighted that the key competitive issue is label simplicity versus Bristol Myers Squibb's offering, underscoring the approval’s strategic importance for Cytokinetics’ market positioning and near-term commercial prospects.

Analysis

Market structure: Cytokinetics (CYTK) is the immediate winner — FDA approval for Myqorzo meaningfully de-risks commercial launch and should capture early-adopter oHCM share from competitors, notably Bristol Myers (BMY), whose label complexity may blunt uptake. Addressable US oHCM patients are low-to-mid tens of thousands initially, so peak sales are likely in the high hundreds of millions to low-single-digit billions depending on pricing and access; expect 20–40% market-share swings in relevant HCM cohorts over 12–36 months.

Risk assessment: Key tail risks are payer restriction/step therapy and real-world safety signals that could trigger label changes or utilization limits; probability of payer pushback is material in the first 3–9 months as PBMs negotiate price. Near term (days–weeks) expect elevated equity and IV volatility; short term (3–12 months) real-world uptake, formulary placements and pricing; long term (2–5 years) depend on durability vs BMY and new entrants plus manufacturing/supply consistency.

trade implications: Prefer directional exposure to CYTK size-constrained: tactical long equity (2–3% portfolio) and a defined-risk options structure — buy 6–9 month CYTK call spread using ~0.5-delta long call and sell ~0.15-delta call to fund cost; hedge pharma revenue risk with a 0.5–1% notional short BMY put spread (3–6 month, 10% OTM) instead of outright short. Rotate 1–2% from large-cap cardiology incumbents into small-cap biotech/launch stories; take profits on quick 20–40% moves and reassess at first sales release (quarterly).

contrarian angles: Market may underprice payer resistance and overprice head-to-head displacement of BMY — BMY’s Camzyos still retains incumbency in some cohorts and large-cap balance sheet reduces existential risk. Historical parallels (early PCSK9, PCSK9 pricing/access hangups) show steep initial rallies followed by access-driven plateaus; expect 30–50% IV compression after the initial post-approval window, creating opportunity to sell short-dated calls or tighten spreads.

Key Decisions for Investors

• Establish a 2–3% long position in CYTK equity within 48 trading hours; scale half immediately and reserve the other half to add on a pullback of 10–15% from entry; set a hard stop loss at -30% to limit binary launch risk.
• Implement a defined-risk options trade: buy a 6–9 month CYTK call (~0.50 delta) and sell a farther OTM call (~0.15 delta) to form a bull-call spread sized to represent 2–3% portfolio exposure; target 80–150% upside, max loss = premium paid.
• Initiate a hedge by buying a 3–6 month BMY put spread (10% OTM) sized to 0.5–1% of portfolio to protect against near-term revenue downside in cardiology franchises; close on first positive/negative sales release within 60–90 days.
• Reduce 1–2% exposure to large-cap cardiology/legacy heart-drug holders and rotate into 1–2% exposure to other late-stage/small-cap biotech launches; exit or trim CYTK exposure after first quarterly US sales print or if CMS restricts coverage within 90 days.